Addiction 101: Understanding addiction to provide stigma free whole-person care in medical and social services
In person
Boston Park Plaza, Boston, MA 9 am – 12 pm ET
Join us for this in-person training in Boston.
How does addiction impact the brain? What are current best practices for treatment and support? How can you help patients/clients feel safe reaching out for treatment and support in the first place?
Addiction 101: Understanding addiction to provide stigma free whole-person care in medical and social services will cover the neuroscience of addiction, dive into some of the commonly used medication assisted treatments for opioid use disorders, discuss stigma around addiction, explore strategies for use of person-centered language, introduce trauma informed approaches to care, and harm reduction practices that support whole person care. This course is intended for anyone who is working in the addiction space and/or are interested in learning basic knowledge, skills, and techniques to support their work with individuals experiencing addiction or substance use disorder.
Objectives
- Explain the neuroscience behind addiction and substance use disorders
- Apply the harm reduction framework in a clinic-based setting
- Identify the impact of trauma
- Practice a trauma-informed approach in addiction services navigation
- Recognize the impact of stigma related to PWUD (people who use drugs) and apply skills to mitigate personal bias in their work
Cost: $300 per person
Date: November 1, 2023
Time: 9 am -12 pm ET
Location: Boston Park Plaza, 50 Park Plaza at Arlington Street, Boston, MA 02116-3912
CEUs are available upon course completion. Registration is limited to 50 individuals.
About the instructors
MICHELLE ADYNIEC
Michelle Adyniec is a Senior Clinical Manager at Camden Coalition for the Care Management and Redesign Initiatives Department. Michelle is a registered nurse and has experience working with individuals with medical and social complexities to identify barriers to care and assist in developing person-centered care plans to support reaching personal wellness goals. Much of her work has been specifically focused on maternal health, substance use, and individuals involved with the child welfare and criminal justice systems. Currently, she oversees a maternal health clinical redesign initiative that aims to improve timely access to pregnancy care following emergency room visits.
LAURA SORENSEN
Laura Sorensen serves as the Senior Project Manager for Substance Use, Harm Reduction and Behavioral Health Initiatives at the Camden Coalition. In this role, Laura supports Office Based Addiction Treatment providers and navigators across the state of New Jersey through training, technical assistance, and convenings. Laura provides subject matter expertise in the areas of Harm Reduction, Trauma-informed care, and developing programs and services that provide stigma-free, whole-person care to people who use drugs. Prior to this role, Laura served as the Director of RHD Morris Home, a residential drug and alcohol treatment program for members of the transgender community with a history of homelessness. Laura has trained at the local, state, and national level about best practices for working with members of the LGBTQ community experiencing complex health and social needs. Laura graduated from Temple University with a Master of Social Work in 2014.
DR. CLEMENT CHEN
Dr. Clement Chen studied Pharmacy at the Ernest Mario School of Pharmacy in Rutgers University where he graduated with his Doctorate Degree in Pharmacy as a Phi Lambda Sigma (Pharmacy Leadership Society) graduate. His journey to working in the SUD space began at the Universal Hospital in Newark as a heart failure clinical pharmacist, where many also had comorbid SUD. He is currently the academic detailer and clinical pharmacist specialist for the Northern NJ MAT Center of Excellence since 2019. Dr. Chen is APhA Immunization Certified and is a Board-Certified Pharmacotherapy Specialist. Dr. Clement Chen was involved in the recent publication of: Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states in the Drug and Alcohol Dependence Journal.